Morgan Stanley
XLO icon

Morgan Stanley’s Xilio Therapeutics XLO Stock Holding History

Morgan Stanley’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$546K Sell
56,954
-539
-0.9% -$4.5K ﹤0.01% 5506
2026
Q1 		$484K Sell
57,493
-2,496
-4% -$20.4K ﹤0.01% 5502
2025
Q4 		$538K Sell
59,989
-8,719
-13% -$91.6K ﹤0.01% 5472
2025
Q3 		$811K Sell
68,708
-34,458
-33% -$345K ﹤0.01% 5269
2025
Q2 		$982K Buy
103,166
+20,606
+25% +$218K ﹤0.01% 5109
2025
Q1 		$837K Buy
82,560
+11,034
+15% +$139K ﹤0.01% 5090
2024
Q4 		$956K Sell
71,526
-37,196
-34% -$512K ﹤0.01% 5118
2024
Q3 		$1.2M Buy
108,722
+29,241
+37% +$359K ﹤0.01% 4941
2024
Q2 		$1.05M Buy
79,481
+63,631
+401% +$996K ﹤0.01% 4929
2024
Q1 		$240K Buy
15,850
+6,760
+74% +$65.2K ﹤0.01% 5668
2023
Q4 		$70K Buy
9,090
+7,214
+385% +$143K ﹤0.01% 6059
2023
Q3 		$55.4K Sell
1,876
-54
-3% -$2.01K ﹤0.01% 6124
2023
Q2 		$70.8K Sell
1,930
-251
-12% -$10.7K ﹤0.01% 6082
2023
Q1 		$96.8K Buy
2,181
+352
+19% +$15.5K ﹤0.01% 6015
2022
Q4 		$68.9K Buy
1,829
+1,340
+274% +$45.2K ﹤0.01% 6145
2022
Q3 		$20K Sell
489
-14
-3% -$544 ﹤0.01% 6800
2022
Q2 		$20K Buy
503
+353
+235% +$18.7K ﹤0.01% 6993
2022
Q1 		$14K Buy
150
+76
+103% +$12K ﹤0.01% 7289
2021
Q4 		$17K Buy
+74
New +$17.6K ﹤0.01% 7283

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Morgan Stanley's XLO Position: Q2 2026 in Review

Morgan Stanley reduced its Xilio Therapeutics (XLO) stake by 0.94% in Q2 2026, selling an estimated $4.5K and leaving 56,954 shares worth $546K. The position accounts for ﹤0.01% of the portfolio, ranked #5506.

Morgan Stanley first reported a position in XLO in Q4 2021 and has held it in 19 quarters since. The position peaked at $1.2M in Q3 2024. 26 funds tracked by Wall St. Rank hold XLO as of Q2 2026.

  • Morgan Stanley held 56,954 shares of Xilio Therapeutics worth $546K as of Q2 2026.
  • Morgan Stanley sold 539 Xilio Therapeutics shares in Q2 2026, an estimated $4.5K.
  • Xilio Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5506 holding.
  • Morgan Stanley first reported a position in Xilio Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • Morgan Stanley's Xilio Therapeutics position peaked at $1.2M in Q3 2024.
  • 26 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.